Select year

2026 2025 2024 2023 2022 Earlier

shown/page

5

2025.09.25

Leading with Source Innovation: Chipscreen Biosciences and Chiglitazar Sodium (Bilessglu®) Honored with A Decade of Glory for China's Innovative Drugs Awards
Leading with Source Innovation: Chipscreen Biosciences and Chiglitazar Sodium (Bilessglu®) Honored with A Decade of Glory for China's Innovative Drugs Awards

2025.08.18

Chipscreen Biosciences 2025 Innovation Summit Concludes Successfully: AI + Integrated Core Technology Platform Fuels Original New Drug Development
Chipscreen Biosciences 2025 Innovation Summit Concludes Successfully: AI + Integrated Core Technology Platform Fuels Original New Drug Development

2025.08.07

International Hepatology Journal Publishes Key Study on Chiglitazar Sodium (Bilessglu®) for MASH Treatment
International Hepatology Journal Publishes Key Study on Chiglitazar Sodium (Bilessglu®) for MASH Treatment

2025.07.31

Chipscreen Biosciences' Brain-Penetrant Aurora B Selective Inhibitor CS231295 Tablet Receives FDA IND Approval, Advancing Global Clinical Development
Chipscreen Biosciences' Brain-Penetrant Aurora B Selective Inhibitor CS231295 Tablet Receives FDA IND Approval, Advancing Global Clinical Development

2025.07.27

ESMO 2025丨Chidamide HDAC+IO Study Selected for Featured Presentation
ESMO 2025丨Chidamide HDAC+IO Study Selected for Featured Presentation

Media contact

Media contact

（+86）0755-36993500
pr@chipscreen.com